I am truly hopeful that the Pfizer and other vaccine

New Post Public Reply Private Reply Replies (2) Message Board
Mo Drano #67164
829
I am truly hopeful that the Pfizer and other vaccine candidates are successful. I believe in order for society to get back to some resemblance of normalcy that we need both effective vaccines and effective therapeutics. Approximately 50% of the population will not take a vaccine as has been stated numerous times and verified by numerous polls. If this initial 90% efficacy Pfizer figure were to actually hold up, that would still leave 55% of the entire population that could need a CV19 treatment. If Brilacidin is as successful in upcoming CV19 human trials it could be the standard treatment for a vast majority of the population. There is both a major need and a major market for both effective vaccines and effective therapeutics to fight the CV19 pandemic and future viruses and disease.

I am cautiously optimistic on today’s Pfizer news but there are some critical details that need to be addressed per the attached article.
====================================================
Key information about the vaccine is not yet available. There is no information yet on whether the vaccine prevents severe cases, the type that can cause hospitalization and death.

Nor is there any information yet on whether it prevents people from carrying the virus that causes Covid-19, SARS-CoV-2, without symptoms.

Without more information, it’s too early to start predicting how much of an impact the vaccine could make, said Michael Osterholm, director of the University of Minnesota’s Center for Infectious Diseases Research and Policy.
“I don’t want to dampen any enthusiasm for this vaccine. I just want us to be realistic,” Osterholm said. “For a vaccine to really have maximal impact, it’s going to have to also reduce severe illness and death. And we just don’t know yet.”

Because the vaccine has been studied for only a matter of months, it is impossible to say how long it will protect against infection with the virus.

The vaccine does cause side effects,

The results have not been peer-reviewed by outside scientists or published in a medical journal

Initial supplies of the vaccine, if authorized, will be limited.

The vaccine must be stored at super-cold temperatures, which could make it extremely difficult to deliver it to many places.

the efficacy of the vaccine could change as the study is completed

No mRNA product has ever been approved by regulators.

https://www.statnews.com/2020/11/09/covid-19-...-indicate/



Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 143

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 114

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 407

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 130

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 501

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 372

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Anthropic Bears Get New Tools, But Daily Risk Bites

Updated Category News Views 72

A $81.3 Billion Offering Invites Fast Money Anthropic arrived in public markets with the sort of numbers that make traders reach for both a calculator and a helmet. The company priced 980 million Class A shares at $83 on November 18, 2026, raising roughly $81.3 billion, then opened at $111.50 when it began Nasdaq trading on November 19. That is a monster debut by any...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 744

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
CommBank Yello Builds a Wider Moat Around Customers

Updated Category News Views 10

Nine million customers is not a pilot program; it is a crowded stadium, and CommBank has decided to hand everyone a reason to stay in their seats. Commonwealth Bank's expanded CommBank Yello program now lets eligible customers earn points across home loans, term deposits, cards and insurance, then redeem with well-known brands. That is a serious attempt to make a bank...

Continue Reading

Top 5 Most Recently Viewed Articles

Fullscript's Summit Aims to Transform Whole Person Healthcare

Updated Category News Views 331

Transforming Healthcare Through Comprehensive Approaches Fullscript, a trailblazing healthcare platform, is set to host its highly anticipated Fullscript Forward Health and Tech Summit. This event focuses on innovative strategies and solutions aimed at addressing the pressing challenges currently facing healthcare. The Summit's Core Focus With chronic illness affecting...

Continue Reading
Candel Therapeutics Unveils Promising Pipeline Developments

Updated Category News Views 194

Exciting Progress in Candel Therapeutics' Development Pipeline As a leading biopharmaceutical company, Candel Therapeutics, Inc. (Nasdaq: CADL) is making remarkable strides in the fight against cancer through its innovative viral immunotherapy portfolio. With exciting updates and anticipated milestones on the horizon for 2025, Candel stands poised to make a significant...

Continue Reading
T. Rowe Price Launches Engaging Podcast Featuring Insights

Updated Category News Views 195

Insights from Industry Leaders on "The Angle" Podcast T. Rowe Price, a renowned global investment management firm, has recently released a new episode of its investment-themed podcast named "The Angle." This series explores pressing topics that shape financial markets, featuring insightful conversations with influential CEOs and leaders in the industry. Meredith Kopit...

Continue Reading
Krispy Kreme Stock Surges After Kash Patel's Disclosure; What Now?

Updated Category News Views 300

Krispy Kreme's Stock Performance Krispy Kreme Inc. (NASDAQ: DNUT) has been making headlines lately as its shares have seen notable movement. Recently, the stock jumped 3.81%, reaching $3.27 during after-hours trading, fueled by the disclosure of a significant investment from Federal Bureau of Investigation Director Kash Patel. Patel’s Investment Disclosure During a...

Continue Reading
SpringGreen Welcomes New Franchise Owner Jeremy McDaniel

Updated Category News Views 116

SpringGreen Expands Its Franchise Network SpringGreen is thrilled to announce the successful transfer of its Knoxville franchise to Jeremy McDaniel. With a robust background in the green industry, particularly from management positions in a national lawn care company, McDaniel embodies the brand's commitment to excellence. A Passion for Entrepreneurship McDaniel's journey...

Continue Reading